QUECTEL-WIRELESS
21.6.2022 14:02:48 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced its dual-band multi-constellation GNSS module LC29H . Built using the Airoha AG3335 platform, the LC29H is available in multiple variants and optionally integrates RTK and DR. The LC29H series offers high performance, power-efficient solutions to meet market needs of high-precision positioning at the centimeter and decimeter levels. These modules are perfectly suited to an expanding market for autonomous lawn mowers, drones, precision agriculture, micro-mobility scooters and delivery robots as well as other industrial and autonomous applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005631/en/
“High precision positioning with centimeter level accuracy is becoming increasingly vital for many new IoT applications. Robotics, UAV and industrial applications needing precise navigation are driving new market requirements and we are very excited to launch our newest generation of high-precision positioning modules,” said Patrick Qian, CEO of Quectel. “With our focus of providing best-in-class, easy-to-use and affordable solutions to our customers, we believe the IoT market is ready for mass adoption of cm-level positioning modules for a wide range of scenarios.”
The LC29H concurrently receives and processes signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS maximizes satellite signal availability. The module supports L1 and L5 dual-band signal reception, thereby ensuring that terminals can speed up convergence time, improve positioning accuracy, and achieve fast response times even when the signal is interrupted. The dual band design significantly mitigates the multipath effect experienced near high-rise buildings or in deep urban canyons, and provides reliable positioning performance.
In addition, some versions contain 6-axis IMU inertial sensors (3-axis accelerometer + 3-axis gyroscope), and integrate RTK and DR positioning algorithms, allowing for continuous lane-level accurate positioning in scenarios where the satellite signal is partially or completely blocked, such as underground parking lots, tunnels, urban-canyons or forests. When the satellite signal is re-acquired, the LC29H combines inertial sensor data with GNSS signals, and the integrated navigation can provide fast convergence times and decimeter level positioning accuracies.
In order to improve the performance when used with a passive Antenna, the LC29H has a built-in LNA and an internal SAW filter, ensuring high sensitivity and excellent positioning accuracy.
The LC29H adopts a 12nm process, dual-frequency receiver chip and advanced low-power management, thereby enabling low-power GNSS sensing and position fixing. This makes the module an ideal solution for power-sensitive and battery-powered devices including handheld devices, asset trackers, and shared vehicles.
Featuring an LCC form factor and an industry standard footprint size of 12.2 mm × 16.0 mm × 2.5 mm, the LC29H series design allows for easy system integration and smooth migration of legacy designs to the latest high precision GNSS technologies.
The LC29H is available in four product variants each targeting different application scenarios. The LC29H(EA) offers a perfect solution for a growing market of agricultural drones as well as electricity power detection terminals, and is able to improve the anti-interference capability of complex systems. The LC29H(BA) is well suited to agricultural machinery and specialized vehicles, and the LC29H(DA) can enable centimeter-level accuracy in connected lawnmowers and safety helmets at competitive cost.
Additionally, the LC29H can be bundled with Quectel’s wide range of off-the-shelf and customized GNSS antennas . Both passive and active antennas are provided to satisfy customer requirements for high precision positioning. Customized connector types and cable lengths are available as along with comprehensive antenna design support including simulation and testing services. The manufacturing of customized antenna solutions is also available to fast track customer product development.
The LC29H will be showcased at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com
, LinkedIn
, Facebook
, and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005631/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom